Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Crohn Disease: HELP
Articles from Miscellaneous institutions in Bronx
Based on 2 articles published since 2010

These are the 2 published articles about Crohn Disease that originated from Miscellaneous institutions in Bronx during 2010-2020.
+ Citations + Abstracts
1 Review Fecal microbiota transplant - a new frontier in inflammatory bowel disease. 2018

Sunkara, Tagore / Rawla, Prashanth / Ofosu, Andrew / Gaduputi, Vinaya. ·Division of Gastroenterology and Hepatology, The Brooklyn Hospital Center, Mount Sinai Health System, New York, NY, USA. · Department of Internal Medicine, Sovah Health, Martinsville, VA, USA, rawlap@gmail.com. · Division of Gastroenterology, SBH Health System, Bronx, NY, USA. ·J Inflamm Res · Pubmed #30214266.

ABSTRACT: Inflammatory bowel disease (IBD) is a chronic multifactorial disease that affects the gastrointestinal tract and results from an aberrant immune response toward luminal antigens in genetically susceptible people. Most of the current therapies for IBD focus on the management of the inflammation by using corticosteroids, immune modulators, and more recently, monoclonal antibodies (biological therapy). Although these therapies provide benefit in most cases, there are still a significant number of patients who do not respond or become refractory over time, suggesting the need for alternative therapeutic options. In the last decade, it has been recognized that "dysbiosis," an imbalanced gut microbiota, is a key element in IBD suggesting microbiome-based therapies as an attractive approach. Recently, fecal microbiota transplant (FMT) has been successfully used for the treatment of

2 Article Methotrexate for the Treatment of Pediatric Crohn's Disease: A Systematic Review and Meta-analysis. 2018

Colman, Ruben J / Lawton, Rachel C / Dubinsky, Marla C / Rubin, David T. ·Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, Illinois. · Pediatrics, SBH Health System, Bronx, New York. · Yale Child Study Center, New Haven, Connecticut. · Mount Sinai School of Medicine, New York, New York. ·Inflamm Bowel Dis · Pubmed #29688409.

ABSTRACT: Background: Methotrexate (MTX) is an immunomodulator used for the treatment of pediatric inflammatory bowel disease (IBD). There are currently no RCTs that assess the treatment efficacy of methotrexate within the pediatric IBD patient population. This systematic review and meta-analysis assesses the efficacy of MTX therapy among the existing pediatric literature. Methods: A systematic literature search was performed using MEDLINE and the Cochrane library from inception until March 2016. Synonyms for 'pediatric', 'methotrexate' and 'IBD' were utilized as both free text and MESH search terms. The studies included contained clinical remission (CR) rates for MTX treatment of pediatric IBD patients 18 yrs old, as mono- or combination therapy. Case studies with <10 patients were excluded. Quality assessment was performed with the Newcastle-Ottawa Scale. Meta-analysis calculated pooled CR rates. A random-effects meta-analysis with forest plots was performed using R. Results: Fourteen (11 monotherapy, 1 combination therapy, 2 both; n = 886 patients) observational studies were eligible out of 202 studies. No interventional studies were identified. The pooled achieved CR rate for pediatric CD patients on monotherapy within 3-6 months was 57.7% (95% CI 48.2-66.6%), (P =0.22; I2 = 29.8%). The CR was 37.1% (95% CI 29.5-45.5%), (P = 0.20; I2 = 37.4%) for maintenance therapy at 12 months. Sub-analysis could not identify CR differences between MTX administration types, thiopurine exposure. Conclusions: This meta-analysis demonstrated that, over 50% of pediatric Crohn's disease patients induced with methotrexate achieved clinical remission, while 12-month remission rate was only 37%. Prospective controlled interventional trials should assess treatment efficacy among patient subgroups. 10.1093/ibd/izy078_video1izy078.video15774883936001.